Ask AI
New Strategies for PNH

CE / CME

Clinical Focus in Paroxysmal Nocturnal Hemoglobinuria: New Strategies for Evading the Complement Cascade

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: March 10, 2026

Expiration: September 09, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, provide an overview of current recommendations for managing paroxysmal nocturnal hemoglobinuria (PNH). Starting with the pathology of the disease and the challenges that delay diagnosis, the module will also present data from pivotal clinical trials that led to the approval of therapeutics targeting the complement cascade. Additional evidence for emerging complement-targeted therapies will be presented that illustrate the various mechanism of action among these drugs. Also included are resources for the patient and information about the management of adverse effects from treatment for the healthcare provider.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with paroxysmal nocturnal hemoglobinuria (PNH) do you provide care for in a typical month?​

For those who practice in academic or community settings, please indicate your practice setting:

A 32-year-old patient presents with sudden-onset fatigue, dark urine in the morning, and mild abdominal discomfort after a recent minor infection. There is no significant history of autoimmune disease or recent transfusion. Which of the following tests in the workup would be most helpful for a timely diagnosis of PNH?

Which of the following approved drugs can prevent both intravascular and extravascular hemolysis as a single agent in patients with PNH?

A 45-year-old woman with classic hemolytic PNH is receiving ravulizumab, which she tolerates well. She continues to have considerable fatigue. Her hemoglobin is 10 g/dL, reticulocyte count is 180 x 109/L, lactate dehydrogenase (LDH) is 270 U/L, and indirect bilirubin is 1.0 mg/L. What would you recommend for this patient as the next step in her care?

In your practice, after diagnosing a patient with PNH and performing baseline monitoring and assessment for thrombosis risk, which of the following would you vaccinate against, or verify vaccination status, before starting treatment?